We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > NUV-422

News List

Nuvation Bio Announces FDA Clearance of Investigational NDA for NUV-422 for the Treatment of Advanced Breast Cancer AmericanPharmaceuticalReview
December 09, 2021
Nuvation Bio Inc. announced that the FDA has cleared its investigational new drug (IND) application to evaluate NUV-422, a cyclin-dependent kinase (CDK) 2/4/6 inhibitor, for the treatment of advanced breast cancer. The FDA accepted the Company's first ...
Nuvation Bio Granted Orphan Drug Designation for NUV-422 for Malignant Gliomas americanpharmaceuticalreview
March 19, 2021
Nuvation Bio announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to NUV-422, a cyclin-dependent kinase (CDK) 2/4/6 inhibitor, for the treatment of patients with malignant gliomas.